Single User License
INR 129040
Site License
INR 258080
Corporate User License
INR 387120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Open-Angle Glaucoma-Pipeline Review, H2 2016

Open-Angle Glaucoma-Pipeline Review, H2 2016


  • Products Id :- GMDHC8409IDB
  • |
  • Pages: 123
  • |
  • August 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Open-Angle Glaucoma-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Open-Angle Glaucoma-Pipeline Review, H2 2016', provides an overview of the Open-Angle Glaucoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma

The report reviews pipeline therapeutics for Open-Angle Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Open-Angle Glaucoma therapeutics and enlists all their major and minor projects

The report assesses Open-Angle Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Open-Angle Glaucoma

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Open-Angle Glaucoma Overview 10

Therapeutics Development 11

Pipeline Products for Open-Angle Glaucoma-Overview 11

Pipeline Products for Open-Angle Glaucoma-Comparative Analysis 12

Open-Angle Glaucoma-Therapeutics under Development by Companies 13

Open-Angle Glaucoma-Therapeutics under Investigation by Universities/Institutes 15

Open-Angle Glaucoma-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Open-Angle Glaucoma-Products under Development by Companies 19

Open-Angle Glaucoma-Products under Investigation by Universities/Institutes 21

Open-Angle Glaucoma-Companies Involved in Therapeutics Development 22

Aerie Pharmaceuticals, Inc. 22

Allergan Plc 23

Amakem NV 24

Bausch & Lomb Incorporated 25

F. Hoffmann-La Roche Ltd. 26

Glaukos Corporation 27

Inotek Pharmaceuticals Corporation 28

Isarna Therapeutics GmbH 29

Kowa Company, Ltd. 30

Laboratoires Thea S.A. 31

Laboratorios Sophia S.A. de C.V. 32

Lee's Pharmaceutical Holdings Limited 33

Lexicon Pharmaceuticals, Inc. 34

Ocular Therapeutix, Inc. 35

Otsuka Holdings Co., Ltd. 36

Oxford BioMedica Plc 37

Sanofi 38

Santen Pharmaceutical Co., Ltd. 39

Senju Pharmaceutical Co., Ltd. 40

Sun Pharma Advanced Research Company Ltd. 41

Sylentis S.A.U. 42

ViSci Ltd. 43

Open-Angle Glaucoma-Therapeutics Assessment 44

Assessment by Monotherapy Products 44

Assessment by Combination Products 45

Assessment by Target 46

Assessment by Mechanism of Action 49

Assessment by Route of Administration 51

Assessment by Molecule Type 53

Drug Profiles 55

(bimatoprost + brimonidine tartarate + timolol maleate)-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

(bimatoprost + timolol maleate)-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

(carteolol hydrochloride + latanoprost)-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

(latanoprost + netarsudil mesylate)-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

(latanoprost + timolol maleate)-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

(latanoprost + trabodenoson)-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

AMA-0076-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Antisense Oligonucleotides to Inhibit P16INK4a for Primary Open-Angle Glaucoma (POAG)-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

bamosiran-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

bimatoprost-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

bimatoprost SR-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

DE-117-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

decorin-Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Glaucoma-GT-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

ISTH-0036-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

latanoprost-Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

latanoprost-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

latanoprost SR-Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

latanoprost SR-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

latanoprostene bunod-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

levobetaxolol hydrochloride-Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

LX-7101-Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

MAN-01-Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

MGV-354-Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

netarsudil mesylate-Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

OPA-6566-Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

PRO-067-Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

R-801-Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

RG-4929-Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

ripasudil-Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

RO-5093151-Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

SAR-366234-Drug Profile 103

Product Description 103

Mechanism Of Action 103

R&D Progress 103

Sepetaprost-Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

SNJ-1656-Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

trabodenoson-Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

travoprost-Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

travoprost SR-Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

travoprost XR-Drug Profile 113

Product Description 113

Mechanism Of Action 113

R&D Progress 113

Open-Angle Glaucoma-Dormant Projects 115

Open-Angle Glaucoma-Discontinued Products 117

Open-Angle Glaucoma-Product Development Milestones 118

Featured News & Press Releases 118

Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting 118

Apr 11, 2016: Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension 118

Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting 119

Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week 119

Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System 120

Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System 121

Appendix 122

Methodology 122

Coverage 122

Secondary Research 122

Primary Research 122

Expert Panel Validation 122

Contact Us 122

Disclaimer 123

List of Figures

Number of Products under Development for Open-Angle Glaucoma, H2 2016 11

Number of Products under Development for Open-Angle Glaucoma-Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Products, H2 2016 18

Assessment by Monotherapy Products, H2 2016 44

Assessment by Combination Products, H2 2016 45

Number of Products by Top 10 Targets, H2 2016 46

Number of Products by Stage and Top 10 Targets, H2 2016 46

Number of Products by Top 10 Mechanism of Actions, H2 2016 49

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 49

Number of Products by Routes of Administration, H2 2016 51

Number of Products by Stage and Routes of Administration, H2 2016 51

Number of Products by Molecule Types, H2 2016 53

Number of Products by Stage and Molecule Types, H2 2016 53

List of Tables

Number of Products under Development for Open-Angle Glaucoma, H2 2016 11

Number of Products under Development for Open-Angle Glaucoma-Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Development by Companies, H2 2016 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Investigation by Universities/Institutes, H2 2016 21

Open-Angle Glaucoma-Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 22

Open-Angle Glaucoma-Pipeline by Allergan Plc, H2 2016 23

Open-Angle Glaucoma-Pipeline by Amakem NV, H2 2016 24

Open-Angle Glaucoma-Pipeline by Bausch & Lomb Incorporated, H2 2016 25

Open-Angle Glaucoma-Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 26

Open-Angle Glaucoma-Pipeline by Glaukos Corporation, H2 2016 27

Open-Angle Glaucoma-Pipeline by Inotek Pharmaceuticals Corporation, H2 2016 28

Open-Angle Glaucoma-Pipeline by Isarna Therapeutics GmbH, H2 2016 29

Open-Angle Glaucoma-Pipeline by Kowa Company, Ltd., H2 2016 30

Open-Angle Glaucoma-Pipeline by Laboratoires Thea S.A., H2 2016 31

Open-Angle Glaucoma-Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016 32

Open-Angle Glaucoma-Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 33

Open-Angle Glaucoma-Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 34

Open-Angle Glaucoma-Pipeline by Ocular Therapeutix, Inc., H2 2016 35

Open-Angle Glaucoma-Pipeline by Otsuka Holdings Co., Ltd., H2 2016 36

Open-Angle Glaucoma-Pipeline by Oxford BioMedica Plc, H2 2016 37

Open-Angle Glaucoma-Pipeline by Sanofi, H2 2016 38

Open-Angle Glaucoma-Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 39

Open-Angle Glaucoma-Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016 40

Open-Angle Glaucoma-Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 41

Open-Angle Glaucoma-Pipeline by Sylentis S.A.U., H2 2016 42

Open-Angle Glaucoma-Pipeline by ViSci Ltd., H2 2016 43

Assessment by Monotherapy Products, H2 2016 44

Assessment by Combination Products, H2 2016 45

Number of Products by Stage and Target, H2 2016 47

Number of Products by Stage and Mechanism of Action, H2 2016 50

Number of Products by Stage and Route of Administration, H2 2016 52

Number of Products by Stage and Molecule Type, H2 2016 54

Open-Angle Glaucoma-Dormant Projects, H2 2016 115

Open-Angle Glaucoma-Dormant Projects (Contd..1), H2 2016 116

Open-Angle Glaucoma-Discontinued Products, H2 2016 117

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aerie Pharmaceuticals, Inc.

Allergan Plc

Amakem NV

Bausch & Lomb Incorporated

F. Hoffmann-La Roche Ltd.

Glaukos Corporation

Inotek Pharmaceuticals Corporation

Isarna Therapeutics GmbH

Kowa Company, Ltd.

Laboratoires Thea S.A.

Laboratorios Sophia S.A. de C.V.

Lee's Pharmaceutical Holdings Limited

Lexicon Pharmaceuticals, Inc.

Ocular Therapeutix, Inc.

Otsuka Holdings Co., Ltd.

Oxford BioMedica Plc

Sanofi

Santen Pharmaceutical Co., Ltd.

Senju Pharmaceutical Co., Ltd.

Sun Pharma Advanced Research Company Ltd.

Sylentis S.A.U.

ViSci Ltd.

Open-Angle Glaucoma Therapeutic Products under Development, Key Players in Open-Angle Glaucoma Therapeutics, Open-Angle Glaucoma Pipeline Overview, Open-Angle Glaucoma Pipeline, Open-Angle Glaucoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com